Comparative Pharmacology
Head-to-head clinical analysis: VAPRISOL versus VAPRISOL IN 5 DEXTROSE IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: VAPRISOL versus VAPRISOL IN 5 DEXTROSE IN PLASTIC CONTAINER.
VAPRISOL vs VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective vasopressin V2 receptor antagonist; inhibits water reabsorption in the collecting duct of the kidney, promoting aquaresis without affecting electrolyte excretion.
Selective vasopressin V2 receptor antagonist; inhibits water reabsorption in the renal collecting duct, leading to aquaresis.
Initial dose: 20 mg IV over 30 minutes, then continuous IV infusion at 20 mg/day for 2-4 days; may increase to 40 mg/day if inadequate response. Maximum duration: 4 days.
IV infusion, initial dose 20 mg once, followed by 20 mg daily if serum sodium increases <5 mEq/L after 24 hours; max 40 mg daily.
None Documented
None Documented
Terminal elimination half-life is approximately 6.5 to 8 hours in patients with normal renal and hepatic function; may be prolonged in hepatic impairment.
Terminal half-life: 10-15 hours; prolonged in renal impairment.
Primarily hepatic metabolism, with approximately 99% of the dose recovered in feces via biliary excretion and less than 1% excreted unchanged in urine.
Renal: 95% as unchanged drug and metabolites; fecal: 5%.
Category C
Category C
Vasopressin Receptor Antagonist
Vasopressin Receptor Antagonist